

MARKET REPORT



Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Pipeline Review, H2 2016

BioPortfolio
Life Science Healthcare and
Pharmaceutical
Market Research and
Corporate Data



Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Pipeline Review, H2 2016

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

We look forward to being of service to you.

If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.

Phone: +44 (0)7887 945155 or **Email:** pdb@bioportfolio.co.uk

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Pipeline Review, H2 2016

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Pipeline Review, H2 2016', provides in depth analysis on Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted pipeline therapeutics.

The report provides comprehensive information on the Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

*Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

- The report provides a snapshot of the global therapeutic landscape for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)

- The report reviews Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Additional Details

Publisher : Global Markets Direct

Reference : GMDHC0645TDB

Number of Pages : 67

Report Format : PDF

Publisher Information :

Global Markets Direct
The home of leading edge research and analysis

BioPortfolio
Life Science Healthcare and Pharmaceutical
Global Market Research and Corporate Data

BioPortfolio
Life Science Healthcare and Pharmaceutical
Market Research and
Corporate Data

**Best Prices
Guaranteed**

bioportfolio.co.uk

Table Of Contents for Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Pipeline Review, H2 2016 [Published by Global Markets Direct]

- Table of ContentsTable of Contents 2List of Tables 5List of Figures 5Introduction 6Global Markets Direct Report Coverage 6Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) Overview 7Therapeutics Development 8Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Products under Development by Stage of Development 8Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Products under Development by Therapy Area 9Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Products under Development by Indication 10Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Pipeline Products Glance 12Late Stage Products 12Early Stage Products 13Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Products under Development by Companies 14Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Products under Development by Universities/Institutes 17Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Therapeutics Assessment 19Assessment by Monotherapy/Combination Products 19Assessment by Mechanism of Action 20Assessment by Route of Administration 21Assessment by Molecule Type 23Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Companies Involved in Therapeutics Development 25Array BioPharma Inc. 25Bristol-Myers Squibb Company 26Genentech, Inc. 27Nimbus Therapeutics, LLC 28Pfizer Inc. 29Portola Pharmaceuticals, Inc. 30Sareum Holdings Plc 31Takeda Pharmaceutical Company Limited 32Theravance Biopharma Inc 33Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Drug Profiles 34ARRY-111 - Drug Profile 34Product Description 34Mechanism Of Action 34R&D Progress 34cerdulatinib - Drug Profile 35Product Description 35Mechanism Of Action 35R&D Progress 35PF-06700841 - Drug Profile 38Product Description 38Mechanism Of Action 38R&D Progress 38SAR-20347 - Drug Profile 39Product Description 39Mechanism Of Action 39R&D Progress 39SART-1 - Drug Profile 41Product Description 41Mechanism Of Action 41R&D Progress 41SART-29 - Drug Profile 42Product Description 42Mechanism Of Action 42R&D Progress 42SART-33 - Drug Profile 43Product Description 43Mechanism Of Action 43R&D Progress 43Small Molecule to Inhibit TYK2 for Immunology - Drug Profile 44Product Description 44Mechanism Of Action 44R&D Progress 44Small Molecule to Inhibit TYK2 for Psoriasis and IBD - Drug Profile 45Product Description 45Mechanism Of Action 45R&D Progress 45Small Molecules to Inhibit TYK2 - Drug Profile 46Product Description 46Mechanism Of Action 46R&D Progress 46Small Molecules to Inhibit Tyk2 for Oncology, Psoriasis and IBD - Drug Profile 47Product Description 47Mechanism Of Action 47R&D Progress 47Synthetic Peptides to Inhibit Tyrosine Kinase 2 for Inflammatory Diseases - Drug Profile 48Product Description 48Mechanism Of Action 48R&D Progress 48TD-1473 - Drug Profile 49Product Description 49Mechanism Of Action 49R&D Progress 49Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Dormant Projects 51Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Discontinued Products 52Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Featured News & Press Releases 53Oct 24, 2016: Sareum Holdings: Successful Outcome from TYK2 Feasibility Study 53Oct 04, 2016: Theravance Biopharma Announces First Subject Dosed in Phase 1b Clinical Trial of TD-1473 in Patients With Moderate to Severe Ulcerative Colitis 53Jun 09, 2016: Theravance Biopharma Reports Positive Results From Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor 54Jun 01, 2016: Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings 55Apr 14, 2016: Portola Pharmaceuticals Announces Upcoming Cerdulatinib Data Presentation at American Association for Cancer Research (AACR) Annual Meeting 2016 56Mar 18, 2016: Theravance Biopharma Presents Positive Results From a Preclinical Colitis Model for TD-1473, a GI-Targeted Pan-Janus Kinase (JAK) Inhibitor 57Dec 10, 2015: Theravance Biopharma Announces First Subject Dosed in Phase 1 Clinical Trial of TD-1473, a GI-Targeted Pan-Janus Kinase Inhibitor 58Dec 05, 2015: Portola Pharmaceuticals Announces Cerdulatinib Data Presentation at the 2015 American Society of Hematology Annual Meeting and Exposition 58Nov 10, 2015: Nimbus Therapeutics Announces Progress on Key Therapeutic Programs 59Nov 02, 2015: Theravance Biopharma Submits Investigational New Drug Application for TD-1473, a GI-Targeted Pan-Janus Kinase Inhibitor 60Jun 17, 2015: Sareum Notified Of Funding Award From Innovate UK 60May 29, 2015: Portola Pharmaceuticals Presents Updated Data From Ongoing Phase 1/2a Study of Dual Kinase Inhibitor Cerdulatinib 61May 18, 2015: Portola Pharmaceuticals Announces Upcoming Data Presentation on Dual Kinase Inhibitor Cerdulatinib at American

Society of Clinical Oncology Annual Meeting 63Nov 10, 2014: Sareum Holdings First Patent Grant for Sareum's TYK2 Kinase Inhibitor Programme 64Nov 06, 2014: Portola Pharmaceuticals Announces Upcoming Presentations on Cerdulatinib at the American Society of Hematology 2014 Annual Meeting 64Appendix 66Methodology 66Coverage 66Secondary Research 66Primary Research 66Expert Panel Validation 66Contact Us 66Disclaimer 67

How to Buy...

Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 2.7.10.2) - Pipeline Review, H2 2016
[Published by Global Markets Direct]

Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/31930>

Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at pdb@bioportfolio.co.uk
or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

Your Name:

Job Title:

Your Email:

Your Contact Phone:

Company Name:

Address:

Post/Zip Code:

Country:

P.O. Number:

Any Other Instructions:

Pricing Options: (please tick one)

- \$2975** | Single User Price
- \$5950** | Site License Price
- \$8925** | Enterprise License Price

Payment Options: (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

Authorising Signature:

Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.